Project Name: LUFT ASCVD Capacity Support Collaborative Working Project

Projet Summary: 

The Collaborative Working Project with Liverpool University Hospitals NHS Foundation Trust (“LUFT”), is designed to address atherosclerotic cardiovascular disease (“ASCVD”) resource capacity challenges by funding an additional Lead Cardiac Rehab CNS, Advanced Clinical Cardiology Pharmacist, and Administrative Support with the aim of enabling the following:

  • Support ASCVD resource capacity by employing a Lead Cardiac Rehab CNS, Advanced Clinical Cardiology Pharmacist, and Administrative Support.
  • Ensure high risk ASCVD patients are identified and treated in a timely manner, therefore reducing risk of further cardiac events.
  • Alleviate capacity constraints by providing one additional clinical day per week, processing 20 extra patients, with 2 full reviews per patient over the year.
  • Secondary Care: Build a replicable patient pathway and template for referrals from other specialties (such as vascular, diabetes, stroke, and renal).
  • Primary Care: Creation of a detailed discharge plan for GPs, aligned with ICS-level initiatives on lipid management (patients who require secondary care intervention will remain under the care of secondary care).
  • Cardiac Rehabilitation: Implement and undertake extended patient group sessions with cardiac rehab focusing on CVD prevention techniques and lifestyle changes.
  • Development of a Business Case to enable continuation and inform wider adoption.
     

Expected Benefits: 

Anticipated Benefits for Patients:

  • Increased patient access to cardiac rehabilitation.
  • Improved patient outcomes and experience through the integration of primary and secondary care pathways.
  • Improvement in waiting times.
  • Earlier identification and access to ASCVD diagnosis and treatments.
  • Increased patient knowledge on cardiac rehabilitation.
     

Anticipated Benefits for the Organisation(s):

  • Improvement in capacity for HCPs in ASCVD services through improved referral processes, treatment pathways, and better-informed patients.
  • Improved collaboration and communication between secondary and primary care for ASCVD patients.
  • Identification of sub-optimally treated ASCVD patients who are at high risk of cardiovascular events and who otherwise may have been missed or left untreated.
     

Anticipated Benefits for Novartis:

  • Better understanding of the overall landscape of patient care within ASCVD in Cheshire and Merseyside.
  • Novartis is likely to see positive outcomes as a result of the CWP.  As more patients are reviewed there is a potential for greater utilisation of Novartis’ licensed medicines, in line with national and local guidelines, where appropriate.
  • Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisations.
  • Enhanced reputation supporting Novartis' vision to provide high quality Collaborative Working with healthcare organisations, to help address some of the issues surrounding health inequalities.
     

Start Date & Duration: April 2026, 18 months 

FA-11635735 | March 2026